{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:41:08Z","timestamp":1792802468910,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":788,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1093\/annonc\/mdx289","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T15:11:10Z","timestamp":1496329870000},"page":"2169-2178","source":"Crossref","is-referenced-by-count":244,"title":["Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma"],"prefix":"10.1016","volume":"28","author":[{"given":"M.","family":"Dreyling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.E.","family":"Assouline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Linton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Vitolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Hiemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Giurescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Garcia-Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Gorbatchevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Koechert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.H.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.L.","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx289_bb0010","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx289_bb0015","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia","volume":"21","author":"de Claro","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx289_bb0020","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-14-2522","article-title":"FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma","volume":"21","author":"Miller","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx289_bb0025","unstructured":"Center for Drug Evaluation and Research. Application number: 206545Orig1s000. Medical Review(s). Clinical Review. Zydelig\u00ae (Idelalisib). http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206545Orig1s000MedR.pdf (20 March 2017, date last accessed)."},{"key":"10.1093\/annonc\/mdx289_bb0030","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.seminoncol.2016.11.011","article-title":"PI3K signaling pathway in normal B cells and indolent B-cell malignancies","volume":"43","author":"Pongas","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdx289_bb0035","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/14737140.2017.1285702","article-title":"Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow","volume":"17","author":"Greenwell","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1093\/annonc\/mdx289_bb0040","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx289_bb0045","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","article-title":"P110\u03b1-mediated constitutive PI3K signaling limits the efficacy of p110\u03b4-selective inhibition in mantle cell lymphoma, particularly with multiple relapse","volume":"121","author":"Iyengar","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx289_bb0050","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2016-12-758599","article-title":"Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL","volume":"130","author":"Erdmann","year":"2017","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx289_bb0055","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ccell.2016.12.003","article-title":"Simultaneous inhibition of PI3K\u03b4 and PI3K\u03b1 induces ABC-DLBCL regression by blocking BCR-dependent and -independent activation of NF-\u03baB and AKT","volume":"31","author":"Paul","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdx289_bb0060","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","article-title":"BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models","volume":"12","author":"Liu","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdx289_bb0065","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","article-title":"First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas","volume":"27","author":"Patnaik","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx289_bb0070","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx289_bb0075","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx289_bb0080","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","article-title":"Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-\u03b4, as therapy for previously treated indolent non-Hodgkin lymphoma","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx289_bb0085","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx289_bb0090","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx289_bb0095","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdx289_bb0100","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx289_bb0105","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx289_bb0110","article-title":"Duvelisib (IPI-145), a phosphoinositide-3-kinase-\u03b4,\u03b3 inhibitor, shows activity in patients with relapsed\/refractory T-cell lymphoma","volume":"124","author":"Horwitz","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdx289_bb0115","unstructured":"U.S. Food & Drug Administration. FDA alerts healthcare professionals about clinical trials with Zydelig (idelalisib) in combination with other cancer medicines. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm490618.htm (20 March 2017, date last accessed)."},{"key":"10.1093\/annonc\/mdx289_bb0120","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutr\u00e9","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdx289_bb0125","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1097\/PAS.0000000000000522","article-title":"Idelalisib-associated colitis: histologic findings in 14 patients","volume":"39","author":"Weidner","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1093\/annonc\/mdx289_bb0130","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/PDM.0b013e31815d0588","article-title":"Mutations of the PIK3CA gene in diffuse large B cell lymphoma","volume":"17","author":"Baohua","year":"2008","journal-title":"Diagn Mol Pathol"},{"key":"10.1093\/annonc\/mdx289_bb0135","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/10428190902803651","article-title":"Infrequent occurrence of PIK3CA mutations in chronic lymphocytic leukemia","volume":"50","author":"Marincevic","year":"2009","journal-title":"Leuk Lymphoma"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419352482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419352482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/9\/2169\/24169777\/mdx289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T04:27:29Z","timestamp":1624681649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419352482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0923753419352482"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx289","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727738600.793539754","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}